drugset / Trial / NCT04585737
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine
Timeline
- Start
- 2020-10-05
- Primary completion
- 2023-08-03
- Completion
- 2023-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bictegravir / Emtricitabine / Tenofovir Alafenamide | Unknown | 25 mg | — |
| Comparator | Bictegravir / Emtricitabine / Tenofovir Alafenamide | Unknown | 50 mg | — |
| Comparator | Bictegravir / Emtricitabine / Tenofovir Alafenamide | Unknown | 200 mg | — |
| Subject | Dolutegravir / Lamivudine | Unknown | 50 mg | Oral |
| Subject | Dolutegravir / Lamivudine | Unknown | 300 mg | Oral |